Revance Therapeutics Inc

Latest Results (06.11.2025):

Revance Therapeutics Inc reported its financial results for the third quarter of 2024, showing solid net revenue growth and steady expense management amid significant corporate and partnership developments. The company’s total net revenue increased by 11% year-over-year to $59.9 million, driven by higher sales volumes of both DAXXIFY and the RHA® Collection. While overall operating expenses remained largely consistent, Revance achieved a slightly lower net loss from continuing operations compared to the prior year. Additionally, the quarter included strategic updates such as a merger agreement with Crown Laboratories and expanded distribution partnerships, although the company has withdrawn its previous financial guidance and will not be hosting a conference call for these results.

Revenue Growth

Revance Therapeutics Inc's third quarter 2024 net revenue reached $59.9 million, up from $54.1 million in the same period last year, reflecting an 11% increase primarily due to a higher sales volume of DAXXIFY and the RHA® Collection. The revenue composition included $30.5 million from the RHA® Collection, $28.3 million from DAXXIFY, and $1.1 million from collaboration revenue.

Expense Management and Net Loss

The company managed its expenses effectively with selling, general, and administrative (SG&A) expenses decreasing and total operating expenses holding steady. Despite the investments in marketing and the launch of DAXXIFY for cervical dystonia, net loss from continuing operations narrowed slightly to $38.1 million from $39.4 million year-over-year, indicating improved cost management.

Strategic Partnership and Merger Developments

In addition to robust financial performance, Revance Therapeutics Inc advanced significant corporate initiatives. The company entered into a merger agreement with Crown Laboratories, Inc. with a tender offer priced at $6.66 per share, and extended the commencement date for the tender offer to November 12, 2024. Furthermore, enhancements to the distribution agreements with Teoxane have been established for the U.S. and expanded to Australia and New Zealand.

Regulatory and Market Expansion

The quarter also saw important market expansion efforts, highlighted by the recent regulatory approval in Mainland China for DAXXIFY aimed at improving the appearance of moderate to severe glabellar lines. This milestone positions Revance Therapeutics Inc to further grow its international footprint and capitalize on emerging market opportunities.